Search

Your search keyword '"Feldmann, G."' showing total 1,021 results
Start Over Author "Feldmann, G."
1,021 results on '"Feldmann, G."'

1. First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison

Author

Mahn R, Glüer OA, Sadeghlar F, Möhring C, Zhou T, Anhalt T, Monin MB, Kania A, Glowka TR, Feldmann G, Brossart P, Kalff JC, Schmidt-Wolf IGH, Strassburg CP, and Gonzalez-Carmona MA

Subjects
hcc, first-line therapy, subgroups, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Robert Mahn,1,&ast; Oscar André Glüer,1,&ast; Farsaneh Sadeghlar,1 Christian Möhring,1 Taotao Zhou,1 Thomas Anhalt,1 Malte Benedikt Monin,1 Alexander Kania,2 Tim R Glowka,2 Georg Feldmann,3 Peter Brossart,3 Joerg C Kalff,2 Ingo GH Schmidt-Wolf,4 Christian P Strassburg,1 Maria A Gonzalez-Carmona1 1Department of Internal Medicine I, University Hospital of Bonn, Bonn, Germany; 2Department of Surgery, University Hospital of Bonn, Bonn, Germany; 3Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany; 4Department of Integrated Oncology CIO Bonn, University Hospital of Bonn, Bonn, Germany&ast;These authors contributed equally to this workCorrespondence: Maria A Gonzalez-Carmona, Department of Internal Medicine I, University Hospital of Bonn, Venusberg-Campus 1, Bonn, 53127, Germany, Tel +49 228 287 15216, Fax +49 228 287 14322, Email maria.gonzalez-carmona@ukbonn.deBackground and Aim: There are several existing systemic 1st- line therapies for advanced hepatocellular carcinoma (HCC), including atezolizumab/bevacizumab (Atez/Bev), sorafenib and lenvatinib. This study aims to compare the effectiveness of these three 1st-line systemic treatments in a real-world setting for HCC, focusing on specific patient subgroups analysis.Methods: A total of 177 patients with advanced HCC treated with Atez/Bev (n = 38), lenvatinib (n = 21) or sorafenib (n = 118) as 1st line systemic therapy were retrospectively analyzed and compared. Primary endpoints included objective response rate (ORR), progression-free survival (PFS) and 15-month overall survival (15-mo OS). Subgroups regarding liver function, etiology, previous therapy and toxicity were analyzed.Results: Atez/Bev demonstrated significantly longer median 15-month OS with 15.03 months compared to sorafenib with 9.43 months (p = 0.04) and lenvatinib with 8.93 months (p = 0.05). Similarly, it had highest ORR of 31.6% and longest median PFS with 7.97 months, independent of etiology. However, significantly superiority was observed only compared to sorafenib (ORR: 4.2% (p < 0.001); PFS: 4.57 months (p = 0.03)), but not comparing to lenvatinib (ORR: 28.6% (p = 0.87); PFS: 3.77 months (p = 0.10)). Atez/Bev also resulted in the longest PFS in patients with Child-Pugh A and ALBI 1 score and interestingly in those previously treated with SIRT. Contrary, sorafenib was non inferior in patients with impaired liver function.Conclusion: Atez/Bev achieved longest median PFS and 15-mo OS independent of etiology and particularly in patients with stable liver function or prior SIRT treatment. Regarding therapy response lenvatinib was non-inferior to Atez/Bev. Finally, sorafenib seemed to perform best for patients with deteriorated liver function.Keywords: HCC, first-line therapy, subgroups

Published
2024

2. Lutetium-177-PSMA-Radioligandentherapie: Konsensus im Rahmen der GKV-finanzierten Versorgung zwischen den Hochschulkliniken in Aachen, Bonn, Düsseldorf, Essen und Köln und dem MDK Nordrhein

Author

Ahmadzadehfar, H., Albers, P., Bockisch, A., Boegemann, M., Böhme, C., Burchert, W., Dietlein, M., Drzezga, A., Fabry, U., Feldmann, G., Heidenreich, A., Heinzel, A., Herrmann, K., Heyll, A., Höhling, C., Kreuzer, C., Laufer, D., Mengel, R., Mottaghy, F. M., Müller, H-W., Müller, S. C., Ost, E., Rahbar, K., Reifenhäuser, W., Schäfers, M., Schlenkhoff, C., Schmidt, M., Schmidt-Wolf, I., Wildenhain, C., Zimmer, B., and Essler, M.

Published
2018
Full Text
View/download PDF

6. Hedgehog Signalweg Aktivierung während akuter Schädigung und Regeneration des exokrinen Pankreas

Author

Fendrich, V., Maitra, A., Esni, F., Feldmann, G., Leach, S. D., Bruch, H. P., editor, Büchler, M. W., editor, Buhr, H. J., editor, Hohenberger, W., editor, Klar, E., editor, Kremer, B., editor, Post, S., editor, Schilling, M., editor, Schumpelick, V., editor, Siewert, J. R., editor, Thiede, A., editor, Becker, H., editor, Bittner, R., editor, Függer, R., editor, Köckerling, F., editor, Saeger, H. D., editor, Zornig, C., editor, Hölscher, A., editor, Izbicki, J. R., editor, Junginger, T., editor, Senninger, N., editor, Allgayer, H., editor, Broll, R., editor, Bruns, C. J., editor, Fries, H., editor, Kalthoff, H., editor, Schackert, H. K., editor, Ertel, W., editor, Faist, E., editor, Holzheimer, R. G., editor, Holzmann, B., editor, Schade, U. F., editor, Vollmar, B., editor, Brückner, U. B., editor, Heidecke, C. D., editor, Menger, M. D., editor, Neugebauer, E., editor, Spiegel, H. U., editor, Biemer, E., editor, Germann, G., editor, Haas, N., editor, Machens, H. G., editor, Stark, G. B., editor, Steinau, H. U., editor, Haverich, A., editor, Heberer, M., editor, Rogiers, X., editor, Jauch, K. W., editor, Roth, H., editor, von Schweinitz, D., editor, Waag, K. L., editor, Altendorf-Hofmann, A., editor, Celik, I., editor, Lehnert, T., editor, Lorenz, W., editor, Ohmann, C., editor, Bechstein, W. O., editor, Broelsch, C., editor, Hopt, U., editor, Klempnauer, J., editor, Neuhaus, P., editor, Fändrich, F., editor, Markus, B., editor, Minor, T., editor, Wonigeit, K., editor, Dralle, H., editor, Goretzki, P. E., editor, Rothmund, M., editor, Bühren, V., editor, Josten, C., editor, Muhr, G., editor, Nast-Kolb, D., editor, Stürmer, K. M., editor, Trentz, O., editor, Brunkwall, J., editor, Sandmann, W., editor, Schmitz-Rixen, T., editor, Storck, M., editor, Branscheid, D., editor, Dienemann, H., editor, Hirner, A., editor, Passlick, B., editor, Toomes, H., editor, Beyersdorf, F., editor, Hetzer, R., editor, Schäfers, H. J., editor, Zerkowski, H. R., editor, Becker, H. D., editor, Saeger, H. -D., editor, Jauch, K. -W., editor, and Bauer, H., editor

Published
2006
Full Text
View/download PDF

9. Epitheliale-mesenchymale Transitionen in Nebenschilddrüsenneoplasien

Author

Karakas, E., Waldmann, J., Feldmann, G., Schlosser, K., König, A., Ramaswamy, A., Bartsch, D. K., Fendrich, V., Buhr, H. J., editor, Hölscher, A., editor, Izbicki, J. R., editor, Jauch, K. W., editor, Post, S., editor, Allgayer, H., editor, Bartsch, D. K., editor, Fries, H., editor, Ghadimi, B. M., editor, Habermann, J. K., editor, Kalthoff, H., editor, Schackert, H. K., editor, Bruns, C. J., editor, Duda, D. N., editor, Fändrich, F., editor, Heberer, M., editor, Nüssler, A. K., editor, Stark, G. B., editor, Brückner, U. B., editor, Ertel, W., editor, Faist, E., editor, Heidecke, C. D., editor, Kalff, J. C., editor, Menger, M. D., editor, Schade, U. F., editor, Vollmar, B., editor, Bechstein, W. O., editor, Klar, E., editor, Klempnauer, J., editor, Minor, T., editor, Neuhaus, P., editor, Schmidt, J., editor, Langer, S., editor, Laschke, M. W., editor, Machens, H. G., editor, Steinau, H. U., editor, Südkamp, N., editor, Vogt, P., editor, Berger, D., editor, Klinge, U., editor, Schachtrupp, A., editor, Schilling, M. K., editor, Schumpelick, V., editor, Altendorf-Hofmann, A., editor, Bollschweiler, E., editor, Bruch, H. -P., editor, Lehnert, T., editor, Lorenz, W., editor, Neugebauer, E., editor, Ohmann, C., editor, Seiler, C. M., editor, Becker, H., editor, Betzler, M., editor, Bittner, R., editor, Broelsch, C., editor, Büchler, M. W., editor, Bumm, R., editor, Dralle, H., editor, Friess, H., editor, Frilling, A., editor, Germer, C. T., editor, Hopt, U., editor, Jonas, S., editor, Jost, J., editor, Markus, B., editor, Raab, H. R., editor, Reith, H. B., editor, Schlag, P. M., editor, Teichmann, W., editor, Uhl, W., editor, Wenisch, H., editor, and Zornig, C., editor

Published
2009
Full Text
View/download PDF

10. MicroRNA miR-155 ist ein Biomaker früher Formen des Pankreaskarzinoms

Author

Habbe, N., Koorstra, J. -B. M., Mendell, J. T., Feldmann, G., Mullendore, M. E., Goggins, M. G., Maitra, A., Buhr, H. J., editor, Hölscher, A., editor, Izbicki, J. R., editor, Jauch, K. W., editor, Post, S., editor, Allgayer, H., editor, Bartsch, D. K., editor, Fries, H., editor, Ghadimi, B. M., editor, Habermann, J. K., editor, Kalthoff, H., editor, Schackert, H. K., editor, Bruns, C. J., editor, Duda, D. N., editor, Fändrich, F., editor, Heberer, M., editor, Nüssler, A. K., editor, Stark, G. B., editor, Brückner, U. B., editor, Ertel, W., editor, Faist, E., editor, Heidecke, C. D., editor, Kalff, J. C., editor, Menger, M. D., editor, Schade, U. F., editor, Vollmar, B., editor, Bechstein, W. O., editor, Klar, E., editor, Klempnauer, J., editor, Minor, T., editor, Neuhaus, P., editor, Schmidt, J., editor, Langer, S., editor, Laschke, M. W., editor, Machens, H. G., editor, Steinau, H. U., editor, Südkamp, N., editor, Vogt, P., editor, Berger, D., editor, Klinge, U., editor, Schachtrupp, A., editor, Schilling, M. K., editor, Schumpelick, V., editor, Altendorf-Hofmann, A., editor, Bollschweiler, E., editor, Bruch, H. -P., editor, Lehnert, T., editor, Lorenz, W., editor, Neugebauer, E., editor, Ohmann, C., editor, Seiler, C. M., editor, Becker, H., editor, Betzler, M., editor, Bittner, R., editor, Broelsch, C., editor, Büchler, M. W., editor, Bumm, R., editor, Dralle, H., editor, Friess, H., editor, Frilling, A., editor, Germer, C. T., editor, Hopt, U., editor, Jonas, S., editor, Jost, J., editor, Markus, B., editor, Raab, H. R., editor, Reith, H. B., editor, Schlag, P. M., editor, Teichmann, W., editor, Uhl, W., editor, Wenisch, H., editor, and Zornig, C., editor

Published
2009
Full Text
View/download PDF

11. Aktivierung von Snail und Sonic Hedgehog bei neuroendokrinen Tumoren des Ileums

Author

Fendrich, Volker, Waldmann, J., Esni, F., Ramaswamy, A., Mullendore, M., Maitra, A., Feldmann, G., Bruch, H. P., editor, Büchler, M. W., editor, Buhr, H. J., editor, Hohenberger, W., editor, Klar, E., editor, Post, S., editor, Schilling, M., editor, Schumpelick, V., editor, Siewert, J. R., editor, Thiede, A., editor, Becker, H., editor, Bittner, R., editor, Függer, R., editor, Köckerling, F., editor, Saeger, H. D., editor, Zornig, C., editor, Hölscher, A., editor, Izbicki, J. R., editor, Jauch, K. W., editor, Senninger, N., editor, Allgayer, H., editor, Bruns, C. J., editor, Celik, I., editor, Fries, H., editor, Kalthoff, H., editor, Schackert, H. K., editor, Brückner, U. B., editor, Ertel, W., editor, Faist, E., editor, Holzheimer, R. G., editor, Holzmann, B., editor, Schade, U. F., editor, Vollmar, B., editor, Heidecke, C. D., editor, Menger, M. D., editor, Neugebauer, E., editor, Spiegel, H. U., editor, Germann, G., editor, Haas, N., editor, Langer, S., editor, Machens, H. G., editor, Stark, G. B., editor, Steinau, H. U., editor, Haverich, A., editor, Heberer, M., editor, Fitze, G., editor, Roth, H., editor, von Schweinitz, D., editor, Waag, K. L., editor, Altendorf-Hofmann, A., editor, Lehnert, T., editor, Lorenz, W., editor, Ohmann, C., editor, Bechstein, W. O., editor, Broelsch, C., editor, Hopt, U., editor, Klempnauer, J., editor, Fändrich, F., editor, Markus, B., editor, Minor, T., editor, Neuhaus, P., editor, Wonigeit, K., editor, Dralle, H., editor, Goretzki, P. E., editor, Rothmund, M., editor, Bühren, V., editor, Josten, C., editor, Muhr, G., editor, Nast-Kolb, D., editor, Stürmer, K. M., editor, Trentz, O., editor, Brunkwall, J., editor, Sandmann, W., editor, Schmitz-Rixen, T., editor, Storck, M., editor, Branscheid, D., editor, Dienemann, H., editor, Hirner, A., editor, Passlick, B., editor, Toomes, H., editor, Beyersdorf, F., editor, Hetzer, R., editor, Schäfers, H. J., editor, Steinsträßer, L., editor, Vogt, P., editor, Arbogast, R., editor, and Bauer, H., editor

Published
2008
Full Text
View/download PDF

12. Die Überexpression der onkogenen Kras-Mutation G12D im adulten Pankreas führt zur Entstehung von highgrade PanIN-Läsionen in Ela-CreERT2;LSL-KrasG12D-Mäusen

Author

Habbe, Nils, Meguid, R. A., Fendrich, V., Feldmann, G., Hruban, R. H., Leach, S. D., Maitra, A., Bruch, H. P., editor, Büchler, M. W., editor, Buhr, H. J., editor, Hohenberger, W., editor, Klar, E., editor, Post, S., editor, Schilling, M., editor, Schumpelick, V., editor, Siewert, J. R., editor, Thiede, A., editor, Becker, H., editor, Bittner, R., editor, Függer, R., editor, Köckerling, F., editor, Saeger, H. D., editor, Zornig, C., editor, Hölscher, A., editor, Izbicki, J. R., editor, Jauch, K. W., editor, Senninger, N., editor, Allgayer, H., editor, Bruns, C. J., editor, Celik, I., editor, Fries, H., editor, Kalthoff, H., editor, Schackert, H. K., editor, Brückner, U. B., editor, Ertel, W., editor, Faist, E., editor, Holzheimer, R. G., editor, Holzmann, B., editor, Schade, U. F., editor, Vollmar, B., editor, Heidecke, C. D., editor, Menger, M. D., editor, Neugebauer, E., editor, Spiegel, H. U., editor, Germann, G., editor, Haas, N., editor, Langer, S., editor, Machens, H. G., editor, Stark, G. B., editor, Steinau, H. U., editor, Haverich, A., editor, Heberer, M., editor, Fitze, G., editor, Roth, H., editor, von Schweinitz, D., editor, Waag, K. L., editor, Altendorf-Hofmann, A., editor, Lehnert, T., editor, Lorenz, W., editor, Ohmann, C., editor, Bechstein, W. O., editor, Broelsch, C., editor, Hopt, U., editor, Klempnauer, J., editor, Fändrich, F., editor, Markus, B., editor, Minor, T., editor, Neuhaus, P., editor, Wonigeit, K., editor, Dralle, H., editor, Goretzki, P. E., editor, Rothmund, M., editor, Bühren, V., editor, Josten, C., editor, Muhr, G., editor, Nast-Kolb, D., editor, Stürmer, K. M., editor, Trentz, O., editor, Brunkwall, J., editor, Sandmann, W., editor, Schmitz-Rixen, T., editor, Storck, M., editor, Branscheid, D., editor, Dienemann, H., editor, Hirner, A., editor, Passlick, B., editor, Toomes, H., editor, Beyersdorf, F., editor, Hetzer, R., editor, Schäfers, H. J., editor, Steinsträßer, L., editor, Vogt, P., editor, Arbogast, R., editor, and Bauer, H., editor

Published
2008
Full Text
View/download PDF

14. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer

Author

Feldmann, G., Habbe, N., Dhara, S., Bisht, S., Alvarez, H., Fendrich, V., Beaty, R., Mullendore, M., Karikari, C., Bardeesy, N., Ouellette, M.M., Yu, W., and Maitra, A.

Subjects
Pancreatic cancer -- Patient outcomes, Pancreatic cancer -- Genetic aspects, Pancreatic cancer -- Research, Pancreatic beta cells -- Physiological aspects, Cellular signal transduction -- Physiological aspects, Cellular signal transduction -- Research, Animal models in research -- Usage, Health
Published
2008

32. Theranostics in nuclear medicine practice

Author

Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, Feldmann G, Ahmadzadehfar H, and Essler M

Subjects
theranostics, nuclear medicine, personalized medicine, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282
Abstract

Anna Yordanova,1 Elisabeth Eppard,2 Stefan Kürpig,2 Ralph A Bundschuh,3 Stefan Schönberger,4 Maria Gonzalez-Carmona,5 Georg Feldmann,6 Hojjat Ahmadzadehfar,1 Markus Essler1 1Department of Nuclear Medicine (Clinical Nuclear Medicine), 2Department of Nuclear Medicine (Radiochemistry), 3Department of Nuclear Medicine (Medical Physics and PET), 4Department of Paediatric Haematology and Oncology, 5Department of Medicine 1, 6Department of Medicine 3, University Hospital Bonn, Bonn, Germany Abstract: The importance of personalized medicine has been growing, mainly due to a more urgent need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets can help predict if a patient will benefit from a particular treatment. Thanks to the quick development of radiopharmaceuticals and diagnostic techniques, the use of theranostic agents has been continually increasing. In this article, important milestones of nuclear therapies and diagnostics in the context of theranostics are highlighted. It begins with a well-known radioiodine therapy in patients with thyroid cancer and then progresses through various approaches for the treatment of advanced cancer with targeted therapies. The aim of this review was to provide a summary of background knowledge and current applications, and to identify the advantages of targeted therapies and imaging in nuclear medicine practices. Keywords: theranostics, nuclear medicine, personalized medicine, PET/CT, therapy, diagnostics

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results